Mark Cuban’s $100 Fine Fix: Can Penalties Tame Healthcare’s Middlemen?

Mark Cuban has a blunt proposal. Fine insurers and providers $100 every time they overbill, wrongly deny care or misrepresent patient costs. Do that enough times, he says, and the money could wipe out the national debt.

The billionaire investor and co-founder of Mark Cuban Cost Plus Drug Company laid out the idea on X on Christmas Eve 2025. “If we fined insurers and providers $100 every time they over-billed, incorrectly denied care or misrepresented any amount of patient out of pocket, we could pay off the national debt,” he wrote. He followed with a call to break them up. “They play on the fear and information asymmetry that exists in healthcare.”

His frustration runs deeper than one post. For years Cuban has attacked the pharmacy benefit managers, or PBMs, that sit between drugmakers, pharmacies, insurers and patients. Those middlemen, he argues, prioritize profits over care. They obscure prices. They steer business to their own operations. And they leave independent pharmacies on the hook for punishing fees.

One pharmacist’s $200,000 penalty reveals the pressure.

In a 2024 guest post on Drug Channels, Cuban described a conversation with an independent pharmacist staring down $200,000 in fines. “That is going to put them out of business,” he wrote. Another pharmacist faced penalties if patients failed to pick up medications within 30 days. The examples illustrate what Cuban calls outright financial abuse.

He listed five core problems with the dominant PBMs. Zero transparency comes first. Contracts bar discussion of terms. Violators risk lawsuits. Next, the creation of “specialty” labels for ordinary generics that let captive pharmacies charge up to 100 times more. Patients have reported paying vastly higher prices for drugs like imatinib or droxidopa through PBM-directed channels than they would at Cost Plus.

Rebates distort incentives. Cuban insists CEOs often fail to grasp that these payments effectively come from the sickest and oldest employees. Higher deductibles follow. Out-of-pocket costs rise. Formularies then favor high-rebate drugs even when cheaper options exist. He points to a Humira biosimilar available on Cost Plus for $594 a month versus more than $8,000 for the brand-name version under some PBM plans. “Formularies should not exist,” Cuban wrote. “Doctors should decide what patients need access to, not the PBMs.”

The fifth charge hits hardest. PBMs squeeze independent pharmacies through direct and indirect remuneration fees, audits and under-reimbursement. Pharmacies buy inventory at one price. They may lose money filling certain scripts. Many transfer brand prescriptions to big chains, severing patient relationships. Cuban did not mince words. “S———ing is the appropriate word to describe the financial abuse.”

His company offers a contrast. Launched in 2022, Mark Cuban Cost Plus Drug Company buys generics at manufacturer cost, adds a 15% markup plus a $5 dispensing fee and $10 shipping. Prices appear plainly on the site. No rebates. No hidden contracts. The model has drawn attention and sales. Recent analysis shows that for many generics, cash prices at Cost Plus beat insurance copays.

Yet the broader system resists change. The Federal Trade Commission sued the three largest PBMs and their group purchasing organizations in September 2024. The complaint accused them of inflating insulin prices by favoring high-list-price products to maximize rebates. The PBMs denied the claims and defended their role in negotiating savings for plan sponsors. An earlier FTC report estimated PBMs marked up drugs by $7.3 billion above acquisition costs.

Cuban sees that figure as conservative. In a January 2026 interview with Fortune, he said abuse in the system runs “far more than $7.3 billion.” He agreed the $38 trillion national debt dwarfs any single fix. Still, he argued fines would alter behavior. “And obviously those being fined would change their behavior.”

His solution remains straightforward. Government agencies, states and self-insured employers should drop the big three PBMs. Switch to independent operators that avoid rebates. Transparency would follow. Trust could return. “At Cost Plus Drugs, our product is trust,” he wrote in the Drug Channels post. “We believe that trust comes with transparency.”

The push has echoes in other efforts. Blue Shield of California ditched CVS Caremark as its PBM. Amazon and others have entered the generic space. Employers grow restless. Yet entrenched interests fight back. PBMs argue their scale delivers net savings that transparent models cannot match at volume. Cuban counters that the opacity hides the true cost to patients and taxpayers.

But his latest idea goes further. Apply the same logic he once used in the NBA. He paid fines for criticizing referees. He kept talking. Now he suggests the healthcare industry face similar accountability. A $100 penalty per violation sounds small. Multiply it across millions of claims and the sums grow large. Enough, perhaps, to grab attention.

Cuban’s track record mixes success and limits. Cost Plus has expanded its catalog to thousands of drugs and partnered with independent pharmacies through a discount card. It proves low prices are possible without middlemen. But it serves a fraction of the market. Most Americans still navigate insurance, formularies and surprise bills.

Recent reporting shows the conversation continues. In April 2026, Semafor detailed Cuban’s warnings that PBMs threaten manufacturers who sell directly to Cost Plus by downgrading their formulary placement. He has taken those concerns to the FTC and Justice Department.

And six hours ago, reports emerged that Cuban continues to press for transparency rules that would force carriers and hospitals to reveal true costs or face consequences. The momentum builds slowly. One pharmacist’s near-closure. One patient’s 100-fold overpayment. One billionaire’s willingness to say the system is broken.

Whether $100 fines ever become policy remains uncertain. Cuban knows ideas alone do not shift trillion-dollar industries. Yet his point lands. Opaque billing and denied claims cost real money. Make the penalty real. Watch behavior change. The alternative is more of the same. Higher costs. Less trust. And a national debt that keeps climbing while patients pay the price.

So far, few have matched Cuban’s directness. He calls for replacement of the big PBMs within five years. He shows his prices openly. He talks to struggling pharmacists. The data from his company and the FTC reports back him up. The question now falls to employers, regulators and lawmakers. Will they keep paying for complexity? Or will they demand the transparency Cuban says is long overdue?